RDB15495 - pENTER-EGFR C797S/L858R

Resource data sheet
Prev.
Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pENTER-EGFR C797S/L858R

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Catalog number	RDB15495
Resource name	pENTER-EGFR C797S/L858R
Clone info.	Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, C797S and L858R, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment	cDNA was obtained from A549 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone	pENTR (plasmid)
Size of vector backbone	2.6 kb
Selectable markers	Kan^r
Gene/insert name	human EGFR cDNA
Depositor\|Developer	Katayama, Ryohei \|

Other clones in our bank

human EGFR

External Database
human EGFR

Reference sequence

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Terms and conditions set forth by the DEPOSITOR In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)

Ordering Please visit Information of Request for Distribution.[link]
Order form [Credit Card Payment] [Bank Transfer Payment]
Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]

Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.

提供案内 (日本国内) [open/close]

Terms and conditions set forth by the DEPOSITOR	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Ordering	Please visit Information of Request for Distribution.[link] Order form [Credit Card Payment] [Bank Transfer Payment] Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]
Remarks	Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.

提供条件	利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
提供依頼	手続きの詳細は、「提供申込みについて[link]」をご覧ください。提供依頼書 [Word] 提供同意書 (MTA、非営利機関による非営利学術研究用)[Word]
備考	Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB15495	pENTER-EGFR C797S/L858R	DNA solution

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

References and tips

Electronic file

Original reference

original	Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

Further references such as user reports and related articles (go to bottom)

Sequence information

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB15495_A7K8p1-1.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 Region: rrnB T1 ter, attL1, insert 5' Sequence file: RDB15495_A7K8a.seq
>D04925A8_A7K8_2_rrnBT1ter_F2_H04_22_ABI24.ab1 1 AGCCAGATCT TCCGACTGAG CCTTTCGTTT TATTTGATGC CTGGCAGTTC CCTACTCTCG 61 CGTTAACGCT AGCATGGATG TTTTCCCAGT CACGACGTTG TAAAACGACG GCCAGTCTTA 121 AGCTCGGGCC CCAAATAATG ATTTTATTTT GACTGATAGT GACCTGTTCG TTGCAACAAA 181 TTGATGAGCA ATGCTTTTTT ATAATGCCAA CTTTGTACAA AAAAGCAGGC TCCGCGGCCG 241 CCCCCTTCAC CATGCGACCC TCCGGGACGG CCGGGGCAGC GCTCCTGGCG CTGCTGGCTG 301 CGCTCTGCCC GGCGAGTCGG GCTCTGGAGG AAAAGAAAGT TTGCCAAGGC ACGAGTAACA 361 AGCTCACGCA GTTGGGCACT TTTGAAGATC ATTTTCTCAG CCTCCAGAGG ATGTTCAATA 421 ACTGTGAGGT GGTCCTTGGG AATTTGGAAA TTACCTATGT GCAGAGGAAT TATGATCTTT 481 CCTTCTTAAA GACCATCCAG GAGGTGGCTG GTTATGTCCT CATTGCCCTC AACACAGTGG 541 AGCGAATTCC TTTGGAAAAC CTGCAGATCA TCAGAGGAAA TATGTACTAC GAAAATTCCT 601 ATGCCTTAGC AGTCTTATCT AACTATGATG CAAATAAAAC CGGACTGAAG GAGCTGCCCA 661 TGAGAAATTT ACAGGAAATC CTGCATGGCG CCGTGCGGTT CAGCAACAAC CCTGCCCTGT 721 GCAATGTGGA GAGCATCCAG TGGCGGGACA TAGTCAGCAG TGACTTTCTC AGCAACATGT 781 CGATGGACTT CCAGAACCAC CTGGGCAGCT GCCAAAAGTG TGATCCAAGC TGTCCCAATG 841 GGAGCTGCTG GGGTGCAGGA GAGGAGAACT GCCAGAAACT GACCAAAATC ATCTGTGCCC 901 AGCAGTGCTC CGGGCGCTGC CGTGGCAAGT CCCCCCAGTG ACTGCTGCCA CAACCAGTGT 961 GCTGCAGCTG CACAGGCCCC CGGGAGAGCG ACTGCCTGGG TCTGCCGCAA TTTCCGAGAC 1021 GAAGCCACGT GCAAGACACC TGCCCCCCCC ACTCATGCTT CTACAACCCC ACCACGTACA 1081 GATGGATGTG ATCCCCGAAG GTCAAATTAC AGCGTTTGGG GTGCTAC //
Primer: pDONR_R Region: attL2, insert 3' Sequence file: RDB15495_A7K8b.seq
>D04925A8_A7K8_2_pDONR_R_E06_15_ABI24.ab1 1 GCGGACGTCA GGGTACGCTA TGACCATGTA ATACGACTCA CTATAGGGGA TATCAGCTGG 61 ATGGCAAATA ATGATTTTAT TTTGACTGAT AGTGACCTGT TCGTTGCAAC AAATTGATAA 121 GCAATGCTTT CTTATAATGC CAACTTTGTA CAAGAAAGCT GGGTCGGCGC GCCCACCCTT 181 TCATGCTCCA ATAAATTCAC TGCTTTGTGG CGCGACCCTT AGGTATTCTG CATTTTCAGC 241 TGTGGAGCCC TTAAAGATGC CATTTGGCTT GGCTTCCTTG GGAAAGAAGT CCTGCTGGTA 301 GTCAGGGTTG TCCAGGCTAA TTTGGTGGCT GCCTTTCTGG GCCCAGTGGG CAGGGCTGTC 361 GAATGTGCTG TTGACACAGG TGGGCTGGAC AGTGTTGAGA TACTCGGGGT TGCCCACTGC 421 AGTGCTGTGG GGGTCCTGGT AGTGTGGGTC TCTGCTGGGC GCGGGGTTCA GAGGCTGATT 481 GTGATAGACA GGATTCTGCA CAGAGCCAGC GGGCCTTTTG GGAACGGACT GGTTTATGTA 541 TTCAGGCACT GGGAGGAAGG TGTCGTCTAT GCTGTCCTCA GTCAAGGCGC CTGTGGGGTC 601 TGAGCTGTAT CGCTGCAAGA AGCTGTCTTC CTTGATGGGA CAGCTTTGCA GCCCATTTCT 661 ATCAATGCAA GCCACGGTGG AATTGTTGCT GGTTGCACTC AGAGAGCTCA GGAGGGGAGT 721 CCGTGACGTG GAGGGGCTGC TGAAGAAGCC CTGCTGTGGG ATGAGGTACT CGTCGGCATC 781 CACCACGTCG TCCATGTCTT CTTCATCCAT CAGGGCACGG TAGAAGTTGG AGTCTGTAGG 841 ACTTGGGCAA ATGCATTCTT TCATCCCCCC TGAATGACAA GGTAGCGCTG GGGGGTCTCG 901 GGCCATTTTG GAGAATTCGA TGATCAACTC ACGGAAACTT TGGGGCGACT ATCTGCGTCT 961 ATCATCCAGC ACTTTGACCA TGATCATGTA GACATCGATG GGTACATATG GGTGGCTGAG 1021 GGAGGGCGTT CTTCGTTTCT CAGGATGGAG GAGATCTCGC TGGGCAGGAA TTTCGTCATA 1081 TGACATGCAA TTCGAAGGTT CAATCCAACC TCCCAAAACA GT //
Primer: EGFR-F5 Region: insert middle region (C797S, L858R) Sequence file: RDB15495_A7K8c.seq
>D04925A8_A7K8_2_EGFR-F5_F06_18_ABI24.ab1 1 AACATAATCG TCATCGCCAC TGGGATGGTG GGGGCCCTCC TCTTGCTGCT GGTGGTGGCC 61 CTGGGGATCG GCCTCTTCAT GCGAAGGCGC CACATCGTTC GGAAGCGCAC GCTGCGGAGG 121 CTGCTGCAGG AGAGGGAGCT TGTGGAGCCT CTTACACCCA GTGGAGAAGC TCCCAACCAA 181 GCTCTCTTGA GGATCTTGAA GGAAACTGAA TTCAAAAAGA TCAAAGTGCT GGGCTCCGGT 241 GCGTTCGGCA CGGTGTATAA GGGACTCTGG ATCCCAGAAG GTGAGAAAGT TAAAATTCCC 301 GTCGCTATCA AGGAATTAAG AGAAGCAACA TCTCCGAAAG CCAACAAGGA AATCCTCGAT 361 GAAGCCTACG TGATGGCCAG CGTGGACAAC CCCCACGTGT GCCGCCTGCT GGGCATCTGC 421 CTCACCTCCA CCGTGCAACT CATCACGCAG CTCATGCCCT TCGGCTCCCT CCTGGACTAT 481 GTCCGGGAAC ACAAAGACAA TATTGGCTCC CAGTACCTGC TCAACTGGTG TGTGCAGATC 541 GCAAAGGGCA TGAACTACTT GGAGGACCGT CGCTTGGTGC ACCGCGACCT GGCAGCCAGG 601 AACGTACTGG TGAAAACACC GCAGCATGTC AAGATCACAG ATTTTGGGCG GGCCAAACTG 661 CTGGGTGCGG AAGAGAAAGA ATACCATGCA GAAGGAGGCA AAGTGCCTAT CAAGTGGATG 721 GCATTGGAAT CAATTTTACA CAGAATCTAT ACCCACCAGA GTGATGTCTG GAGCTACGGG 781 GTGACCGTTT GGGAGTTGAT GACCTTTGGA TCCAAGCCAT ATGACGGAAT CCCTGCCAGC 841 GAGATCTCCT CCATCCTGGG AGAAAGGAGA ACGCCTCCCT CAGCCACCCA TATGTACCAT 901 CGATGTCTAC ATGATCATGG TCAAGTGCTG GATGATAGAC GCAGATAGTC GCCCAAAGTT 961 TCCGTGAGTT TGATCATCGA AATTCTCCCA AAATGGCCCG AGACCCCCAG CGCTACCCTT 1021 TGTTCATTCA AGGGGGAATG AAGAATGCCA TTTGGCTAGG TTCGTACAGA CCTCCGAACT 1081 CTACGCTGCC GTGAATTCAA TGCAGGAAGG ACATTG //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original	Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

2022.05.17

GNP_filter3_RDBDEP_html_220516.pl